Zobrazeno 1 - 10
of 55
pro vyhledávání: '"V. I. Vechorko"'
Autor:
K. V. Komissarova, A. V. Godzenko, D. A. Doroshenko, I. G. Gordeev, O. V. Averkov, V. I. Vechorko
Publikováno v:
Инновационная медицина Кубани, Vol 0, Iss 1, Pp 45-52 (2024)
Introduction: A number of studies uses severity of lung damage as a predictor of lung changes in the long-term period.Objective: To evaluate computed tomography (CT) findings in the long-term period after extremely severe lung damage (CT-4) caused by
Externí odkaz:
https://doaj.org/article/975c3277e09f4009bf32b49235617e6c
Autor:
Yu. V. Shevchuk, A. V. Kryukov, I. I. Temirbulatov, I. V. Sychev, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 3, Pp 228-239 (2023)
Remdesivir is a drug widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during remdesivir therapy reaches 66%, with the most common is an increase in liver function tests.The aim
Externí odkaz:
https://doaj.org/article/6b3b5a75901b45d09a94422a067614ef
Autor:
A. V. Kryukov, A. S. Zhiryakova, Yu. V. Shevchuk, A. V. Matveev, V. I. Vechorko, O. V. Averkov, S. V. Glagolev, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, D. A. Sychev
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 4, Pp 326-344 (2022)
The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential
Externí odkaz:
https://doaj.org/article/5d9ff01bf50b46dfb11a1965a596882f
Autor:
I. I. TEMIRBULATOV, A. V. KRYUKOV, K. B. MIRZAEV, N. P. DENISENKO, S. P. ABDULLAEV, A. S. ZHIRYAKOVA, Y. V. SHEVCHUK, V. I. VECHORKO, O. V. AVERKOV, D. A. SYCHEV
Publikováno v:
Антибиотики и Химиотерапия, Vol 67, Iss 7-8, Pp 45-50 (2022)
The aim of the study was to assess the association of polymorphic variants CYP3A5*3 6986 A>G rs776746 and CYP3A4*22 rs35599367 C>T with the safety parameters of remdesivir therapy in patients with COVID-19.Material and methods. The study included 156
Externí odkaz:
https://doaj.org/article/529d41e696844e8bbf54c26567f38e08
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 21, Iss 6 (2022)
Despite the decrease in the incidence rate, today the problem of a coronavirus disease 2019 (COVID-19) remains relevant on a global scale. Among the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) variants, the Omicron is currently domin
Externí odkaz:
https://doaj.org/article/14df31c1c5124a7a8a83d9aa944a914f
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 21, Iss 3 (2022)
Aim. To study the predictive ability of the NEWS2, 4C Mortality Score, COVID-GRAM and qSOFA scales in predicting clinical outcomes in patients with severe coronavirus disease 2019 (COVID-19) hospitalized in a multidisciplinary hospital.Material and m
Externí odkaz:
https://doaj.org/article/abcfcdddac31463a948d4c747511e9eb
Autor:
O. V. Averkov, V. I. Vechorko
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 9, Pp 64-70 (2019)
Dual antiplatelet therapy serves to improve the clinical results of thrombolytic therapy after STEMI, until recently consisted of acetylsalicylic acid and clopidogrel. In this category of patients, ticagrelor, widely used by acute coronary syndrome a
Externí odkaz:
https://doaj.org/article/d8f790011f5744b0b1baab5971215441
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 18, Iss 1, Pp 150-155 (2019)
The article contains information about the frequency of development of arterial hypertension (AH), the features and causes of its development in patients with peripheral atherosclerosis. AH in patients with chronic atherosclerotic diseases of lower l
Externí odkaz:
https://doaj.org/article/911b2539a8a94b498bd3d51fa76e19f7
Publikováno v:
Медицинский совет, Vol 0, Iss 21, Pp 8-15 (2019)
The article discusses the issues of anticoagulant therapy in pulmonary thromboembolism. It clearly highlights the main advantages and the preferred use of direct selective oral anticoagulants represented by the thrombin inhibitor dabigatran and the f
Externí odkaz:
https://doaj.org/article/19c2d0c4b5644eaa91a9b97bd6e66499
Publikováno v:
Российский кардиологический журнал, Vol 25, Iss 5 (2020)
History of heart transplantation in combination with immunosuppressive therapy and acute viral respiratory infection overlay makes the patient difficult to manage. In case of COVID-19, the setting is complicated by unknown pathogenesis, including its
Externí odkaz:
https://doaj.org/article/1bb3058ed9a14950a6940dd62cc0c30f